LifeStance Health is expanding access to esketamine (Spravato) and transcranial magnetic stimulation (TMS) treatments for patients with treatment-resistant depression across the U.S., doubling the number of locations offering these services from 33 to 69. Analyses show significant reductions in depression severity and suicidal ideation among patients receiving these treatments, with 74% improving after esketamine and 61% after TMS. The expansion aims to help the estimated 2.8 million Americans with treatment-resistant depression, including approximately 139,000 LifeStance patients. LifeStance plans further growth of specialty services in 2027 to improve patient access to effective, evidence-based mental health care.
LifeStance Health's expansion of esketamine and TMS treatments for treatment-resistant depression provides context for mental health sector interest. For readers following health stocks, here is Pluang's market snapshot as of Oct 29, 2026 19:12 WIB: out of 150 priced US health-sector stocks, 91 rose and 53 fell. Notable movers include MESO (Mesoblast Limited) at USD 15.83 with a 1-day change of +18.22% and a typical hold time of 17 days, HLN (Haleon plc) at USD 8.62 down 13.80% with a 15-day hold, and TDOC (Teladoc Health Inc) at USD 7.66 up 11.34% with a 39-day hold time.
The inaugural SportsTech Breakthrough Awards recognized leading companies and technologies advancing sports technology globally. Winners span categories like athlete performance, wearables, AI analytics, fan engagement, and smart stadium solutions, h...
The global Industrial Control System (ICS) Security Market is projected to grow from $17.91 billion in 2026 to $38.48 billion by 2031, at a CAGR of 16.5%. This growth is driven by rising cyberattacks targeting critical infrastructure and the increasi...
AdvantageLumber.com has introduced Sketch-A-Deck, a free online software that simplifies deck design for homeowners and contractors. The tool allows users to draw custom deck layouts, attach them to their homes, and generate build-ready plans with de...
Immunocore Holdings will present Phase 1/2 clinical trial data for brenetafusp alone and combined with KIMMTRAK in treating metastatic uveal melanoma at the 2026 Society for Immunotherapy of Cancer meeting. This trial evaluates safety and efficacy in...
Naples Comprehensive Health (NCH) has completed the first tricuspid valve repair in the US using the PASCAL Precision system following FDA approval. This minimally invasive catheter-based procedure offers a new treatment option for patients with seve...
